ANZ GOG AUSTRALIA NEW ZEALAND GYNAECOLOGICAL ONCOLOGY GROUP

OUTBACK

A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone

Study Chair: Linda Mileshkin
Study Coordinator: Ilka Kolodziej



GYNECOLOGIC CANCER INTERGROUP
An Organization of International Cooperative Groups for Clinical Trials in Gynecologic Cancers

Current status

- 140 Sites open
  - 12 sites in Australia
  - 3 sites in New Zealand
  - 121 sites in the USA
  - 3 sites in Canada
  - 1 site in Saudi Arabia

- 254 Patients recruited
  - 58 patients from Australia
  - 9 patients from New Zealand
  - 185 patients from the USA
  - 2 patients from Saudi Arabia

- First interim analysis completed and approved by IDSMC

- 23 QA reports finalized
  - 5 major deviations
  - 13 minor deviations

- Ongoing high rate of SAEs during chemoRT
  - no SUSARS

Monthly Recruitment



Next steps

- Complete site activations in USA & Canada
- Start trial in Singapore (has now passed RTOG audit)
- Discuss proposal by Dutch Oncology Group to join with specific amendment to allow only them to use IMRT (9 centres)

  - need local arrangement for QA of their RT